

# Thyroid Hormone Action in Fetal Brain Development and Potential for Disruption by Environmental Chemicals

R. THOMAS ZOELLER<sup>1</sup> AND KEVIN M. CROFTON<sup>2\*</sup>

<sup>1</sup>Biology Department, Morrill Science Center, University of Massachusetts, Amherst, MA, USA;

<sup>2</sup>Neurotoxicology Division, Environmental Protection Agency, National Health and Environmental Effects Research Laboratory, US Research Triangle Park, NC, USA

**Abstract:** Thyroid hormone is well-known to play essential roles in brain development. Therefore, environmental factors that interfere with thyroid function or thyroid hormone action may produce deleterious effects on brain development by interfering with thyroid hormone action in the developing brain. Therefore, the purpose of this review is to identify in broad terms the gaps in our knowledge of thyroid hormone action in brain development, to relate these gaps to present information on thyroid disruption, and to review briefly our recent research that is germane to these issues. The endocrinology of the thyroid system is first reviewed briefly with an emphasis on the neuroendocrine and extrathyroidal mechanisms controlling circulating levels of thyroid hormones. The second section reviews the evidence that thyroid hormone is important for fetal, as well as neonatal, brain development. We review the mechanism of thyroid hormone action in the third section and briefly relate this information to information about the mechanism of thyroid hormone action on brain development. In the final section, we review the endocrinology of thyroid disruption with an emphasis on disruption of thyroid hormone action. © 2000 Intox Press, Inc.

**Key Words:** Thyroid Hormone, Endocrine Disruptors, Brain Development

## INTRODUCTION

There is increasing public concern that incidental exposure to environmental chemicals can disrupt hormone signaling during development, thereby causing permanent effects on brain development in humans and wildlife. These concerns are especially grave for disruption of thyroid hormone action because this hormone is an essential factor in normal brain development (Dussault and Ruel, 1987; Escobar *et al.*, 1997; Myant, 1971; Porterfield and Hendrich, 1993; Timiras and Nzekwe, 1989). A growing scientific literature documents the association between concentrations of circulating thyroid hormone and exposure to specific environmental chemicals or chemical mixtures to which we are exposed in our environment. However, there are critical gaps in our understanding of thyroid hormone action on fetal brain development that severely limit our ability to attribute experimental or epidemiological observations to

disruption of thyroid hormone action. Therefore, the purpose of this review is to identify in broad terms the gaps in our knowledge of thyroid hormone action in brain development, to relate these gaps to present information on thyroid disruption, and to review briefly our recent research that is germane to these issues.

## THYROID ENDOCRINOLOGY


The iodothyronines are formed in the thyroid gland from two iodinated tyrosyl residues on the large hormone "precursor", thyroglobulin (TG) (Taurog, 1996). The most important iodothyronines are 3,5,3',5'-tetraiodothyronine (thyroxine, T<sub>4</sub>), 3,5,3'-triiodothyronine (T<sub>3</sub>), and 3,3',5'-triiodothyronine (reverse T<sub>3</sub>). Circulating triiodothyronines are formed largely from peripheral deiodination of T<sub>4</sub>, which is the major product released from the thyroid gland (Leonard and Koehrle, 1996). The pituitary glycoprotein

---

Please send requests for reprints to Dr. R. Thomas Zoeller, Biology Department, Morrill Science Center, University of Massachusetts, Amherst, MA 01003, USA, Phone: 413/545-2088, Fax: 413/545-3243, E-mail: tzoeller@bio.umass.edu

\*This manuscript has been reviewed by the Health Effects Research Laboratory, U.S. Environmental Protection Agency, and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

Submitted: December 31, 1999 Accepted: May 22, 2000



**FIG. 1.** Basic elements of thyroid endocrinology. Numbers in filled diamonds refer to the legend below that provides descriptions of the specific level of the thyroid system.

1. Neurons whose cell bodies reside in the hypothalamic paraventricular nucleus (PVN) synthesize the tripeptide Thyrotropin-Releasing Hormone (TRH) (Segersen et al., 1987a; Segersen et al., 1987b). Although TRH-containing neurons are widely distributed throughout the brain (Jackson et al., 1985; Lechan et al., 1986), TRH neurons in the PVN project uniformly to the median eminence (Ishikawa et al., 1988; Merchenthaler and Liposits, 1994), a neurohemal organ connected to the anterior pituitary gland by the hypothalamic-pituitary-portal vessels (Martin and Reichlin, 1987), and are the only TRH neurons to regulate the pituitary-thyroid axis (Aizawa and Greer, 1981). 2. TRH is delivered by the pituitary-portal vasculature to the anterior pituitary gland to stimulate the synthesis and release of Thyroid Stimulating Hormone (TSH) or "Thyrotropin" (Haisenleder et al., 1992). TSH is one of three glycoprotein hormones of the pituitary gland and is composed of an alpha and a beta subunit (Wondisford et al., 1996a). All three pituitary glycoproteins (Luteinizing Hormone, LH; Follicle Stimulating Hormone, FSH; and TSH) all share the same alpha subunit (Hadley, 2000). TRH selectively stimulates the synthesis of the TSH beta subunit (Haisenleder et al., 1992). However, TRH also affects the post-translational glycosylation of TSH which affects its biological activity (Harel et al., 1993; Lippman et al., 1986; Magner et al., 1992; Taylor et al., 1986; Taylor and Weintraub, 1985; Weintraub et al., 1989). 3. Pituitary TSH binds to receptors on the surface of thyroid follicle cells and stimulates their activity (Taugog, 1996; Wondisford et al., 1996b). This activity includes uptake of iodide, iodide organification, synthesis and oxidation of thyroglobulin (TG), TG uptake from thyroid colloid and production of the iodothyronines T4 and T3. T4 is by far the major product released from the thyroid gland (Taugog, 1996). 4. Thyroid hormones are carried in the blood by specific proteins. In humans, about 75% of T4 is bound to thyroxine-binding globulin (TBG), 15% is bound to transthyretin (TTR) and the remainder is bound to albumin (Schussler, 2000). TBG, the least abundant but most avid T4 binder, is a member of a class of proteins that includes Cortisol Binding Protein and is cleaved by serine proteases in serum (Fink et al., 1986). These enzymes are secreted into blood during inflammatory responses and, in the case of CBP, can induce the release of cortisol at the site of inflammation. The physiological significance of this observation is presently unclear for TBG (Schussler, 2000), but it raises the possibility that TBG may selectively release of T4 under specific circumstances. 5. Thyroid hormones (T4 and T3) exert a negative feedback effect on the release of pituitary TSH (Chopra, 1996; Scanlon and Toft, 1996; Stockigt, 1996) and on the activity of hypothalamic TRH neurons (Koller et al., 1987; Rondeel et al., 1989; Segersen et al., 1987b). Because circulating levels of T4 and of T3 fluctuate considerably within an individual, and because the radioimmunoassays for T4 and for T3 are associated with a fairly high intra-assay coefficient of variation, TSH measurements are considered to be diagnostic of thyroid dysfunction (Chopra, 1996; Roti et al., 1993; Stockigt, 1996). 6. T4 and T3 are actively transported into target tissues (Docter et al., 1997; Everts et al., 1994a; Everts et al., 1994b; Everts et al., 1995; Friesema et al., 1999; Kragie, 1996a; Kragie, 1996b; Moreau et al., 1999; Oppenheimer, 1983). T4 can be converted to T3 by the action of outer-ring deiodinases (ORD, Type I and Type II) (Germain and Galton, 1997). Peripheral conversion of T4 to T3 by these ORDs accounts for nearly 80% of the T3 found in the circulation (Chopra, 1996). 7. Thyroid hormones are cleared from the blood in the liver following glucuronidation by UDP-glucuronosyl transferase (Hood and Klaassen, 2000). These modified thyroid hormones are then eliminated through the bile. 8. T4 and/or T3 are actively concentrated in target cells about 10-fold over that of the circulation. The receptors for T3 (TRs) are nuclear proteins that bind to DNA and regulate transcription (Lazar, 1993; Lazar, 1994; Mangelsdorf and Evans, 1995; Oppenheimer and Schwartz, 1997; Oppenheimer et al., 1994). There are two genes that encode the TRs, c-erbA-alpha (TRa) and c-erbA-beta (TRb). Each of these genes is differentially spliced, forming 3 separate TRs, TRa1, TRb1, and TRb2. The effects of thyroid hormone are quite tissue-, cell-, and developmental stage-specific and it is believed that the relative abundance of the different TRs in a specific cell may contribute to this selective action.

hormone, thyrotropin (TSH) (Wondisford *et al.*, 1996b), regulates the synthesis and secretion of thyroid hormones by activating guanylate cyclase in thyroid follicular cells (Rapoport and Spaulding, 1986). However, there are a number of important extrathyroidal processes that maintain circulating thyroid hormones within a relatively narrow concentration range (Leonard and Koehle, 1996). Normal variation in circulating concentrations of  $T_4$  reflects short-term pulsatile and diurnal variation (Stockigt, 1996).  $T_4$  and/or  $T_3$  exert a negative feedback effect on pituitary secretion of TSH (Morley, 1981; Scanlon and Toft, 1996), and on the hypothalamic secretion of the releasing factor, thyrotropin-releasing hormone (TRH) (Koller *et al.*, 1987; Rondeel *et al.*, 1988; Segersen *et al.*, 1987b), which controls the amount of TSH in the blood. Finally, TRH from the hypothalamus stimulates the pituitary gland to release TSH (Jackson and Lechan, 1983), and modulates the sensitivity of the pituitary gland to negative feedback by thyroid hormone (Greer *et al.*, 1993; Taylor *et al.*, 1990). Thus, circulating levels of thyroid hormones, and the balance between different forms of these hormones, are controlled by a number of processes (Figure 1).

### THYROID HORMONE AND FETAL BRAIN DEVELOPMENT

Despite early work suggesting that the human placenta is impermeable to maternal thyroid hormones (Fisher *et al.*, 1977), it is now well accepted that iodothyronines of maternal origin reach the fetal compartment (Porterfield, 1994; Porterfield and Hendrich, 1993; Porterfield and Stein, 1994). Several recent observations account for this change in perception. First, thyroid hormones have been detected in human coelomic and amniotic fluids as early as 8 weeks of gestation, before the onset of fetal thyroid function at 10-12 weeks (Contempre *et al.*, 1993). Moreover, neonates born with an autosomal disorder resulting in the complete inability to synthesize  $T_4$ , are euthyroid at birth, but become severely hypothyroid as the hormone is metabolically cleared (Vulsma *et al.*, 1989). The maternal thyroid gland was the only source of thyroid hormone in these neonates. In addition, human fetal brain tissues express receptors for thyroid hormone, and receptor occupancy by thyroid hormone is in the range known to produce physiological effects as early as 9 weeks of gestation (Bernal and Pekonen, 1984; Ferreiro *et al.*, 1988). There is also a 3-fold gradient of cytosolic free  $T_3$  to nuclear  $T_3$  in cells of the human fetal brain (Ferreiro *et al.*, 1988), suggesting that compartmentalization of  $T_3$  in brain cells may favor hormone action. These data all suggest that maternal thyroid hormone is delivered to the fetus before the onset of fetal thyroid function, and that the minimum requirements for thyroid hormone signaling are present at this time.

Functional studies indicate that thyroid hormone is essential for normal fetal brain development. For example, iodine administration to pregnant women in their first trimester eliminates the incidence of cretinism in geographic areas that are iodine insufficient. However, by the end of the second trimester, iodine supplementation does not prevent neurological damage (Cao *et al.*, 1994; DeLong *et al.*, 1994), indicating that thyroid hormone plays an important role in brain development perhaps before the onset of fetal thyroid function. In addition, children born to pregnant women with untreated hypothyroidism during the second trimester exhibit measurable neurological deficits despite normal circulating thyroid hormone at birth (Haddow *et al.*, 1999; Pop *et al.*, 1999). Extensive reviews on this issue have been recently published (Delange, 1996; Escobar *et al.*, 1997; Porterfield, 1994; Porterfield and Hendrich, 1993; Porterfield and Stein, 1994). It is clear that the fetus is equipped with a variety of mechanisms to obtain and maintain exposure to maternal thyroid hormones even before the onset of fetal thyroid function, including increased uptake and conversion of  $T_4$  to  $T_3$  (Calvo *et al.*, 1992; Escobar *et al.*, 1997). These data present strong evidence that maternal thyroid hormone play a role in fetal brain development prior to the onset of fetal thyroid function, and that the consequences of thyroid hormone deficits or disruption during pregnancy are neurological and irreversible (Dussault and Walker, 1983; Foley, 1996; Gupta *et al.*, 1995; Klett, 1997; Miculan *et al.*, 1993; Vanderschueren-Lodeweyckx *et al.*, 1983; Vliet, 1999). However, this view is not uniformly held (Fisher, 1999; Schwartz *et al.*, 1997).

### MECHANISM OF THYROID HORMONE ACTION

It is generally held that the majority of biological actions of thyroid hormone are mediated by nuclear receptors for  $T_3$  (Lazar, 1993; Lazar, 1994).  $T_3$  receptors (TRs) are members of the steroid/thyroid superfamily of ligand-dependent transcription factors (Lazar, 1993; Lazar, 1994; Mangelsdorf and Evans, 1995), indicating that effects on gene expression mediate the majority of biological actions of thyroid hormone. TRs are encoded by two genes, designated  $\alpha$  and  $\beta$  *c-erbA* (Sap *et al.*, 1986; Weinberger *et al.*, 1986). These two genes produce three functional TRs: TR $\alpha$ 1, TR $\beta$ 1, and TR $\beta$ 2 (Hodin *et al.*, 1989; Izumo and Mahdavi, 1988; Koenig *et al.*, 1988; Murray *et al.*, 1988; Thompson *et al.*, 1987). Although there are several TRs expressed, the binding affinity for  $T_3$  and for  $T_4$  are not different among the various forms (Oppenheimer, 1983; Oppenheimer *et al.*, 1994; Schwartz *et al.*, 1992). These studies demonstrate that TRs exhibit a 10-fold greater affinity for  $T_3$  than for  $T_4$  and that  $T_3$  is the physiologically important regulator of TR action.

However, TR $\alpha$ 1 and TR $\beta$ 1 exhibit different profiles of binding to the thyroid hormone analogue desethylamioderone (Bakker *et al.*, 1994; Beeren *et al.*, 1995). Therefore, it is possible that other exogenous compounds, specifically environmental chemicals, may bind differentially to these two TRs.

Despite the observation in rats that TRs are expressed in fetal brain (Bradley *et al.*, 1992; Bradley *et al.*, 1989; Falcone *et al.*, 1994; Perez-Castillo *et al.*, 1985; Strait *et al.*, 1990), and that maternal T<sub>4</sub> can cross the placenta and be converted to T<sub>3</sub> (Calvo *et al.*, 1990; Contempre *et al.*, 1993; Escobar *et al.*, 1990; Escobar *et al.*, 1997; Vulsma *et al.*, 1989), few thyroid hormone-responsive genes have been identified in the fetus. In truth, remarkably few studies have even examined thyroid hormone responsiveness of the fetal brain (Bonet and Herrera, 1988; Escobar *et al.*, 1997; Escobar *et al.*, 1988; Geel and Timiras, 1967; Hadjzadeh *et al.*, 1989; Porterfield, 1994; Porterfield and Hendrich, 1993). The lack of information concerning molecular mechanism(s) of thyroid hormone action on brain development has two important consequences. First, we have little appreciation for the molecular events or developmental processes by which thyroid hormone produces the effects observed in humans and animals briefly discussed above. Second, we have no direct measures of thyroid hormone action in fetal brain. Therefore, we cannot directly test the hypothesis that specific chemicals can interfere with thyroid hormone action because the only measures available are indirect such as thyroid hormone concentration in serum or in specific tissues.

To address this weakness, we recently initiated a study to test the hypothesis that maternal thyroid hormone can influence gene expression in the fetal rat brain (Dowling *et al.*, 2000). Our strategy was to identify genes in the fetal cortex that are responsive to acute manipulation of maternal thyroid status. We focused on the embryonic day 16 (E16) fetus because fetal thyroid function does not begin until E17 (Fisher *et al.*, 1977); thus, these genes would be regulated solely by *maternal* thyroid hormone. In addition, E16 is the time when most of the neurons of the cerebral cortex are generated and begin to differentiate (Bayer and Altman, 1995). Our paradigm for thyroid hormone manipulation was also novel among studies designed to identify thyroid hormone-responsive genes. For example, we surgically thyroidectomized female rats two weeks before they were mated to allow thyroid hormones to decline before pregnancy. Next, on G15, we administered two half-doses of T<sub>4</sub> (12.5  $\mu$ g/kg each) so that the concentration of thyroid hormone in the dam's blood would not be supraphysiological. We reasoned that this combination of a physiological dose of T<sub>4</sub> and an acute injection paradigm would allow us to identify genes directly responsive to thyroid hormone and would be physiologically relevant.

We identified a number of genes expressed in the fetal brain that appear to be responsive to maternal

thyroid hormone. Two of these genes, encoding neuroendocrine-specific protein (NSP) (Velde *et al.*, 1994a; Velde *et al.*, 1994b) and Oct-1 (Dominov and Miller, 1996; Kambe *et al.*, 1993; Suzuki *et al.*, 1993), exhibited complementary patterns of expression in the fetal brain and responses to thyroid hormone. Oct-1 mRNA is elevated by T<sub>4</sub> injection and is expressed selectively in the periventricular zone where neuroblasts continue to proliferate. In contrast, NSP mRNA is suppressed by thyroid hormone and was selectively expressed in the intermediate zone where neurons are beginning to differentiate. Oct-1 is a member of the POU-domain family of transcription factors (Dominov and Miller, 1996) that is implicated in the control of neuronal proliferation. NSP is a neural-specific protein associated with endoplasmic reticulum that may be involved in the acquisition of neuronal polarization and differentiation (Senden *et al.*, 1996; Velde *et al.*, 1994b). These experiments demonstrate first that thyroid hormone of maternal origin can affect gene expression in the fetus and provide "biomarkers" of thyroid hormone action in the fetal brain. Second, these data provide circumstantial evidence supporting the view that maternal thyroid hormone may affect proliferation and differentiation of cortical neurons. In addition, because we found that NSP and Oct-1 retain their sensitivity to thyroid hormone in adulthood, our results suggest that the concept of "critical windows" of thyroid hormone action apply to specific developmental events, but probably not to thyroid hormone sensitivity *per se*.

From this perspective, it is easy to imagine that thyroid hormone plays an important role in developmental processes such as neuronal proliferation that occur in different brain areas at different times (Bayer and Altman, 1995). Therefore, the temporal "window" of thyroid hormone sensitivity will depend on the developmental period over which a particular process occurs, and this will differ for different brain areas. For example, in humans, acute disruption of thyroid hormone action selectively during the first trimester might affect proliferation of cortical neurons, but would not affect proliferation of cerebellar granule cells that undergo proliferation in the third trimester. Considering that many endocrine disruptors, such as polychlorinated biphenyls, are lipophilic and accumulate in the body, it is difficult to imagine that there would be selective exposure windows during development. However, it is possible that the congener profile or dose of exposure might be different for fetal versus lactational exposure. Moreover, we are not certain of the roles thyroid hormone plays in different elements of brain development. For example, we know that thyroid hormone affects proliferation of cerebellar granule cells (Eayrs and Taylor, 1951; Nicholson and Altman, 1972), but we still do not know if this is true for cortical neurons. Therefore, lipophilic chemicals may exert temporally specific effects on brain development through the thyroid hormone signaling system because

this system exerts temporally specific effects. In addition, the various TRs may play different roles in brain development (Bradley *et al.*, 1992; Bradley *et al.*, 1994; Forrest *et al.*, 1990), and if different PCB congeners act preferentially on different TRs, the ultimate consequences of this action may represent only a subset of thyroid hormone dependent phenotypes.

## ENDOCRINOLOGY OF THYROID DISRUPTION

The general definition of an endocrine disruptor is "any exogenous agent that interferes with the production, release, transport, metabolism, binding, action, or elimination of natural hormones in the body responsible for the maintenance of homeostasis and the regulation of developmental processes" (Kavlock *et al.*, 1996). Each process in the pathway from hormone production to hormone action is itself composed of several biochemical or physiological steps. Because each of these steps may be an independent site of disruption, it is reasonable to predict that different classes of synthetic or natural environmental chemicals may interfere with a specific hormonal signaling pathway at different steps from hormone production to hormone action. Clearly, this is true for the thyroid system. Environmental agents producing goitrogenic and/or antithyroid effects have been categorized according to chemical class (Gaitan and Cooksey, 1989). These classes range from complex anions such as perchlorate or lithium which block iodide uptake into the thyroid gland (Green, 1996), to halogenated biphenyls, which appear to have a variety of effects on thyroid hormone transport, metabolism, and perhaps hormone binding (Brouwer *et al.*, 1998; Brucker-Davis, 1998; Cheek *et al.*, 1999). However, despite the variety of mechanisms by which goitrogenic or antithyroid agents have been shown to act on the thyroid system, all ultimately affect circulating thyroid hormone concentrations (Brucker-Davis, 1998; Gaitan, 1989; Green, 1996). In fact, it was the effect on circulating thyroid hormone that identified these agents as goitrogens or antithyroid agents initially.

In general, the ability of a chemical to influence circulating levels of thyroid hormone does not necessarily provide a clear indication of its effects on thyroid hormone action, though it is often assumed. For example, PCB exposure does not always produce a compensatory increase in circulating TSH, despite profound reductions in circulating levels of thyroid hormone (reviewed in (Brouwer *et al.*, 1998; Kolaja and Klaassen, 1998)), suggesting that unidentified individual PCB congeners may suppress TSH (Brouwer *et al.*, 1998; Kolaja and Klaassen, 1998). In addition, developmental exposure to PCBs advances the onset of eye opening in rats (Goldey *et al.*, 1995), an event associated with hyperthyroidism. Children exposed to high levels of PCBs can

exhibit hyperactivity (Guo *et al.*, 1994), a symptom that also may be associated with subclinical hyperthyroidism (Suresh *et al.*, 1999). Finally, we have recently shown that developmental exposure to PCBs can increase the expression of two thyroid hormone-responsive genes in the developing brain; namely, RC3/Neurogranin, and myelin basic protein (Zoeller *et al.*, 2000). Thus, in the case of PCBs, their ability to reduce circulating levels of thyroid hormone is not uniformly associated with effects consistent with hypothyroidism.

Although PCBs do not exert effects fully consistent with hypothyroidism, they do produce specific effects that appear to be mediated by reduced thyroid hormone concentrations. For example, PCB exposure reduces circulating levels of thyroid hormone and produces hearing loss in rats (Goldey *et al.*, 1995) that can be partially ameliorated by  $T_4$  administration (Goldey and Crofton, 1998). In addition,  $T_4$  can normalize the PCB-induced suppression of choline acetyltransferase activity in the forebrain of neonatal rats (Ku *et al.*, 1994). Finally, postnatal PCB exposure can increase testis size of the adult rat (Cooke *et al.*, 1996), an effect that is identical to that of perinatal treatment with goitrogens (Cooke *et al.*, 1993). Taken together, these data suggest that PCBs can produce effects consistent with an antithyroid action as well as effects consistent with a thyroid hormone-like action.

PCBs are a class of industrial compounds consisting of paired biphenyl rings with various degrees of chlorination (Tilson and Kodavanti, 1997). The pattern of chlorine substitution on the biphenyl rings can produce a structure that appears to be similar to that of thyroxine (Chauhan *et al.*, 1999). Several studies have shown that individual PCB congeners can bind to thyroxine-binding proteins with high affinity (Brouwer *et al.*, 1998). Specifically, individual PCB congeners can bind to transthyretin (Chauhan *et al.*, 1999), intracellular  $T_4$ -binding sites (Brundl and Buff, 1993) and nuclear  $T_4$ -binding sites (McKinney *et al.*, 1987). However, the evidence that PCBs can bind to the classic thyroid hormone receptor is weak. Cheek *et al.* (1999) have recently shown that some individual PCB congeners can bind to the human TR $\beta$ 1 with a very low affinity ( $K_1 = 30\mu\text{M}$ ). It seems unlikely that this would be of physiological significance. However, there are a large number of PCB congeners present in common mixtures, and there are a large number of possible metabolic modifications (Seegal, 1996; Tilson *et al.*, 1998). Perhaps some individual congeners do bind to the TR, or alter their ability to respond to thyroid hormone.

An alternate, or additional, mechanism by which PCB exposure may produce a thyroid hormone-like effect on the developing brain is by enhancing thyroid hormone uptake into tissues and increasing the conversion of  $T_4$  to  $T_3$ . Specifically, PCB-induced hypothyroxinemia may increase cellular uptake of  $T_4$  or  $T_3$  and increase the expression of deiodinases responsible for intracellular conversion of  $T_4$  to  $T_3$ . Tissue uptake of  $T_3$  or  $T_4$  is elevated by reduced levels of

thyroxine (Everts *et al.*, 1994b; Friesema *et al.*, 1999; Moreau *et al.*, 1999) which also increases the expression of type II deiodinase in brain (Burmeister *et al.*, 1997; Germain and Galton, 1997). However, these processes are affected by hypothyroxinemia caused by goitrogens or PCBs, yet the two kinds of chemicals produce very different effects on thyroid hormone-responsive measures. Therefore, the differences in effects of these two treatments may not arise from the induction of compensatory mechanisms alone. Clearly, further work is required to understand the role of T<sub>4</sub> transport and deiodination in the regulation of thyroid hormone action during periods of hypothyroxinemia caused by different agents.

## CONCLUSIONS

Clinical studies show that maternal thyroid hormone reaches the fetus and that fetal hypothyroidism can produce neurological deficits. Experimental work is beginning to confirm that thyroid hormone of maternal origin can reach the fetus and affect gene expression in the fetal brain. Therefore, factors that affect thyroid hormone action in the fetal brain, either directly or indirectly by disrupting maternal thyroid economy, have the potential to affect brain development. However, the developmental processes affected by thyroid hormone during fetal life, the molecular mechanisms mediating these thyroid hormone effects, the developmental periods during which thyroid hormone is important for a particular event, and the ultimate consequences to brain function in the adult, are poorly understood. Until these issues are better understood, it will be difficult to determine the full extent of thyroid disruption and to link thyroid disruption to specific measures of intellectual performance.

The extremely pleiotropic nature of thyroid hormone action will also present a challenge to those working in the field of thyroid disruption. For example, thyroid hormone induces a negative transcriptional effect on the gene encoding TRH (Hollenberg *et al.*, 1995), but this only occurs in TRH neurons located in the hypothalamic paraventricular nucleus (Koller *et al.*, 1987; Segersen *et al.*, 1987b; Zoeller *et al.*, 1993), despite the widespread distribution of TRH in TR-containing neurons throughout the brain (Bradley *et al.*, 1992; Segersen *et al.*, 1987a). Another example is that Oct-1 expression is enhanced by thyroid hormone before birth, but suppressed by thyroid hormone after birth, in the same tissue (Dowling *et al.*, 1998). Therefore, evaluating the effect of thyroid disruptors on thyroid hormone action will require an appreciation for this plasticity.

The molecular mechanism(s) believed to be responsible for the variable effects of thyroid hormone action reveal the possibility that thyroid action can be

disrupted without affecting hormone delivery to the cell. Thyroid hormone receptors are believed to require the formation of heterodimers with other transcription factors, including receptors for retinoids or vitamin D, to affect the expression of some genes (Lazar, 1993; Lazar, 1994; Mangelsdorf and Evans, 1995). Therefore, disruption of retinoic acid signaling may disrupt thyroid hormone action without affecting circulating concentrations of thyroid hormones or TSH. This same logic applies to the many types of proteins that have been shown to interact with TRs, including corepressors and coactivators (Koenig, 1998). Although speculative, it would explain why PCB exposure produces effects in animals which simultaneously appear to be anti-thyroid and thyroid hormone-like.

## ACKNOWLEDGEMENTS

Preparation of this manual was supported in part by a Grant from the National Institute of Environmental Health Sciences ES10026 to R. Thomas Zoeller.

## REFERENCES

- Aizawa T, Greer MA.** Delineation of the hypothalamic area controlling thyrotropin secretion in the rat. *Endocrinology* 1981; 109:1731-1738
- Bakker O, Beeren HCv, Wiersinga WM.** Desethylamiodarone is a noncompetitive inhibitor of the binding of thyroid hormone to the thyroid hormone beta-1 receptor protein. *Endocrinology* 1994; 134:1665-1670
- Bayer SA, Altman J.** Neurogenesis and neuronal migration. In: *The Rat Nervous System, Second Edition*, G. Paxinos, eds., San Diego, CA. Academic Press, 1995
- Beeren HCv, Bakker O, Wiersinga WM.** Desethylamiodarone is a competitive inhibitor of the binding of thyroid hormone to the alpha-1 receptor protein. *Mol Cell Endocrinol* 1995; 112:15-19
- Bernal J, Pekonen F.** Ontogenesis of the nuclear 3,5,3'-triiodothyronine receptor in the human fetal brain. *Endocrinology* 1984; 114:677-679
- Bonet B, Herrera E.** Different response to maternal hypothyroidism during the first and second half of gestation in the rat. *Endocrinology* 1988; 122:450-455
- Bradley DJ, Towle HC, Young WS.** Spatial and temporal expression of alpha- and beta-thyroid hormone receptor mRNAs, including the beta-2 subtype, in the developing mammalian nervous system. *J Neurosci* 1992; 12:2288-2302
- Bradley DJ, Towle HC, Young WS.** Alpha and beta thyroid hormone receptor (TR) gene expression during auditory neurogenesis: evidence for TR isoform-specific transcriptional regulation *in vivo*. *Proc Natl Acad Sci USA* 1994; 91:439-443

- Bradley DJ, WS Young I, Weinberger C.** Differential expression of alpha and beta thyroid hormone receptor genes in rat brain and pituitary. *Proc Natl Acad Sci USA* 1989; 86:7250-7254
- Brouwer A, Morse DC, Lans MC, Schuur AG, Murk AJ, Klasson-Wehler E, Bergman A, Visser TJ.** Interactions of persistent environmental organohalides with the thyroid hormone system: mechanisms and possible consequences for animal and human health. *Toxicol Ind Health* 1998; 14:59-84
- Brucker-Davis F.** Effects of environmental synthetic chemicals on thyroid function. *Thyroid* 1998; 8:827-856
- Brundl A, Buff K.** Partial purification and characterization of a rat liver polychlorinated biphenyl (PCB) binding protein. *Biochem Pharmacol* 1993; 45:885-891
- Burmeister LA, Pachucki J, Germain DLS.** Thyroid hormones inhibit type 2 iodothyronine deiodinase in the rat cerebral cortex by both pre- and posttranslational mechanisms. *Endocrinology* 1997; 138:5231-5237
- Calvo R, Obregon MJ, Ona CRd, Rey FE, Escobar GMd.** Congenital hypothyroidism, as studied in rats. *J Clin Invest* 1990; 86:889-899
- Calvo R, Obregon MJ, Rey FE, Escobar GMd.** The rat placenta and the transfer of thyroid hormones from the mother to the fetus. Effects of maternal thyroid status. *Endocrinology* 1992; 131:??
- Cao XY, Jiang XM, Dou ZH, Murdon AR, Zhang ML, O'Donnell K, Ma T, Kareem A, DeLong N, DeLong GR.** Timing of vulnerability of the brain to iodine deficiency in endemic cretinism. *N Engl J Med* 1994; 331:1739
- Chauhan KR, Kodavanti PRS, McKinney JD.** Assessing the role of *ortho*-substitution on polychlorinated biphenyl binding to transthyretin, a thyroxine transport protein. *Toxicol Appl Pharmacol* 1999; 162:10-21
- Cheek AO, Kow K, Chen J, McLachlan JA.** Potential mechanisms of thyroid disruption in humans: interaction of organochlorine compounds with thyroid receptor, transthyretin, and thyroid-binding globulin. *Env Hlth Perspectives* 1999; 107:273-278
- Chopra IJ.** Nature, source, and relative significance of circulating thyroid hormones. In: *Werner and Ingbar's The Thyroid, Seventh Edition*, L. E. Braverman and R. D. Utigers, eds., Philadelphia. Lippincott-Raven, 1996, 111-124
- Contempre B, Jauniaux E, Calvo R, Jurkovic D, Campbell S, Escobar GMd.** Detection of thyroid hormones in human embryonic cavities during the first trimester of pregnancy. *J Clin Endocrinol Metab* 1993; 77:1719-1722
- Cooke PS, Kirby JD, Porcelli J.** Increased testis growth and sperm production in adult rats following transient neonatal goitrogen treatment: optimization of the propylthiouracil dose and effects of methimazole. *J Reprod Fertil* 1993; 97:493-499
- Cooke PS, Zhao Y-D, Hansen LG.** Neonatal polychlorinated biphenyl treatment increases adult testis size and sperm production in the rat. *Toxicol Appl Pharmacol* 1996; 136:112-117
- Delange FM.** Endemic Cretinism. In: *Werner and Ingbar's The Thyroid, Seventh Edition*, L. E. Braverman and R. D. Utigers, eds., Philadelphia. Lippincott-Raven, 1996, 756-767
- DeLong GR, Ma T, Cao XY, Jiang XM, Dou ZH, Murdon AR, Zhang ML, Heinz ER.** The neuromotor deficit in endemic cretinism. In: *The Damaged Brain of Iodine Deficiency*. Ed.: J. B. Stanbury. Cognizant Communications, New York, 1994
- Docter R, Friesema ECH, Stralen PGJv, Krenning EP, Everts ME, Visser TJ, Hennemann G.** Expression of rat liver cell membrane transporters for thyroid hormone in *Xenopus laevis* oocytes. *Endocrinology* 1997; 138:1841-1846
- Dominov JA, Miller JB.** POU homeodomain genes and myogenesis. *Dev Genet* 1996; 19:108-118
- Dowling ALS, Martz GU, Darling DS, Zoeller RT.** Thyroid hormone affects the expression of multiple genes in the fetal and adult brain. *Thyroid* 1998; 8 (Suppl 1):64
- Dowling ALS, Martz GU, Leonard JL, Zoeller RT.** Acute changes in maternal thyroid hormone induce rapid and transient changes in specific gene expression in fetal rat brain. *J Neurosci* 2000; 20:2255-2265
- Dussault JH, Ruel J.** Thyroid hormones and brain development. *Annu Rev Physiol* 1987; 49:321-334
- Dussault JH, Walker P.** *Congenital Hypothyroidism*. Dekker, New York, 1983
- Eayrs JE, Taylor SH.** The effect of thyroid deficiency induced by methyl thiouracil on the maturation of the central nervous system. *J Anat* 1951; 85:350-358
- Escobar GMd, Calvo R, Obregon MJ, Rey FE.** Contribution of maternal thyroxine to fetal thyroxine pools in normal rats near term. *Endocrinology* 1990; 126:2765-2767
- Escobar GMd, Obregon MJ, Calvo R, Pedraza P, Rey FE.** Iodine deficiency, the hidden scourge: The rat model of human neurological cretinism. In: *Recent Research Developments in Neuroendocrinology - Thyroid Hormone and Brain Maturation*. Ed.: C. E. Hendrich. Research Signpost, 1997
- Escobar GMd, Obregon MJ, Rey FE.** Transfer of thyroid hormones from the mother to the fetus. In: *Research in Congenital Hypothyroidism*, F. Delang, D. A. Fisher and D. Glinioers, eds., New York. Plenum Press, 1988, 15-28
- Everts ME, Docter R, Moerings EPCM, Koetsveld PMv, Visser TJ, Jong Md, Krenning EP, Hennemann G.** Uptake of thyroxine in cultured anterior pituitary cells of euthyroid rats. *Endocrinology* 1994a; 134:2490-2497
- Everts ME, Visser TJ, Moerings EPCM, Docter R, Toor Hv, Tempelaars AMP, Jong Md, Krenning EP,**

- Hennemann G.** Uptake of triiodothyroacetic acid and its effect on thyrotropin secretion in cultured anterior pituitary cells. *Endocrinology* 1994b; 135:2700-2707
- Everts ME, Visser TJ, Moerings EPCM, Tempelaars AMP, Toor Hv, Docter R, Jong Md, Krenning EP, Hennemann G.** Uptake of 3,5',5,5'-tetraiodothyroacetic acid and 3,3',5'-triiodothyronine in cultured rat anterior pituitary cells and their effects on thyrotropin secretion. *Endocrinology* 1995; 136: 4454-4461
- Falcone M, Miyamoto T, Fierro-Renoy F, Macchia E, DeGroot LJ.** Evaluation of the ontogeny of thyroid hormone receptor isoforms in rat brain and liver using an immunohistochemical technique. *Eur J Endocrinol* 1994; 130:97-106
- Ferreiro B, Bernal J, Goodyer CG, Branchard CL.** Estimation of nuclear thyroid hormone receptor saturation in human fetal brain and lung during early gestation. *J Clin Endocrinol Metab* 1988; 67:853-856
- Fink IL, Bailey TJ, Gustafson TA, Markham BE, Morkin E.** Complete amino acid sequence of human thyroxine-binding globulin deduced from cloned DNA: Close homology to the serine antiproteases. *Proc Natl Acad Sci USA* 1986; 83:7708-7712
- Fisher D, Dussault J, Sack J, Chopra I.** Ontogenesis of hypothalamic-pituitary-thyroid function and metabolism in man, sheep, rat. *Rec Progr Horm Res* 1977; 33:59-107
- Fisher DA.** Hypothyroxinemia in premature infants: Is thyroxine treatment necessary? *Thyroid* 1999; 9:715-720
- Foley TP.** Congenital Hypothyroidism. In: *Werner and Ingbar's The Thyroid, Seventh Edition*, L. E. Braverman and R. D. Utiger, eds., Philadelphia. Lippincott-Raven, 1996, 988-994
- Forrest D, Sjoberg M, Vennstrom B.** Contrasting developmental and tissue-specific expression of alpha and beta thyroid hormone receptor genes. *EMBO J* 1990; 9:1519-1528
- Friesema ECH, Docter R, Moerings EPCM, Stieger B, Hagenbuch B, Meier PJ, Krenning EP, Hennemann G, Visser TJ.** Identification of thyroid hormone transporters. *Biochem Biophys Res Commun* 1999; 254:497-501
- Gaitan E.** *Environmental Goitrogenesis*. CRC Press, Inc, Boca Raton, 1989, pp. 250
- Gaitan E, Cooksey RC.** General Concepts of Environmental Goitrogenesis. In: *Environmental Goitrogenesis*, E. Gaitans, eds., Boca Raton. CRC Press, Inc., 1989, 3-14
- Geel SE, Timiras PS.** The influence of neonatal hypothyroidism and of thyroxine on the RNA and DNA concentration of rat cerebral cortex. *Brain Research* 1967; 4:135-142
- Germain DLS, Galton VA.** The deiodinase family of selenoproteins. *Thyroid* 1997; 7:655-668
- Goldey ES, Crofton KM.** Thyroxine replacement attenuates hypothyroxinemia, hearing loss, and motor deficits following developmental exposure to Aroclor 1254 in rats. *Toxicol Sci* 1998; 45:94-105
- Goldey ES, Kehn LS, Lau C, Rehnberg GL, Crofton KM.** Developmental exposure to polychlorinated biphenyls (Aroclor 1254) reduces circulating thyroid hormone concentrations and causes hearing deficits in rats. *Toxicol Appl Pharmacol* 1995; 135:77-88
- Green WL.** Antithyroid Compounds. In: *Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text*, L. E. Braverman and R. D. Utiger, eds., Philadelphia. Lippincott-Raven, 1996, 266-267
- Greer MA, Sato N, Wang X, Greer SE, McAdams S.** Evidence that the major physiological role of TRH in the hypothalamic paraventricular nuclei may be to regulate the set-point for thyroid hormone negative feedback on the pituitary thyrotroph. *Neuroendocrinology* 1993; 57:569-575
- Guo YL, Chen YC, Yu ML, Hsu CC.** Early development of Yu-Cheng children born seven to twelve years after the Taiwan PCB outbreak. *Chemosphere* 1994; 29:2395-2404
- Gupta RK, Bhatia V, Poptani H, Gujral RB.** Brain metabolite changes on *in vivo* proton magnetic resonance spectroscopy in children with congenital hypothyroidism. *J Pediatr* 1995; 126:389-392
- Haddow JE, Palomaki GE, Allen WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Fais JD, Klein RZ.** Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med* 1999; 341:549-555
- Hadjzadeh M, Sinha AK, Pickard MR, Ekins RP.** Effect of maternal hypothyroxinemia in the rat on brain biochemistry in adult progeny. *J Endocrinol* 1989; 124:387-396
- Hadley ME.** *Endocrinology*. Prentice Hall, Upper Saddle River, NJ, 2000
- Haisenleder DJ, Ortolano GA, Dalkin AC, Yasin M, Marshall JC.** Differential actions of thyrotropin (TSH)-releasing hormone pulses in the expression of prolactin and TSH subunit messenger ribonucleic acid in rat pituitary cells *in vitro*. *Endocrinology* 1992; 130:2917-2923
- Harel G, Kane JP, Shamoun DS, Magner JA, Szabo M.** Effect of thyroid hormone deficiency on glycosylation of rat TSH secreted *in vitro*. *Horm Metab Res* 1993; 25:278-280
- Hodin RA, Lazar MA, Wintman BI, Darling DS, Chin WW.** Identification of a thyroid hormone receptor that is pituitary-specific. *Science* 1989; 244:76-79
- Hollenberg AN, Monden T, Flynn TR, Boers M-E, Cohen O, Wondisford FE.** The human thyrotropin-releasing hormone gene is regulated by thyroid hormone through two distinct classes of negative thyroid hormone response elements. *Molecular Endocrinology* 1995; 9:540-550
- Hood A, Klaassen CD.** Differential effects of microsomal enzyme inducers on *in vitro* thyroxine



- (T4) and triiodothyronine (T3) glucuronidation. *Toxicol Sci* 2000; 55:78-84
- Ishikawa K, Taniguchi Y, Inoue K, Kurosumi K, Suzuki M.** Immunocytochemical delineation of the thyrotrophic area: origin of thyrotropin-releasing hormone in the median eminence. *Neuroendocrinology* 1988; 47:384-388
- Izumo S, Mahdavi V.** Thyroid hormone receptor alpha isoforms generated by alternative splicing differentially activate myosin HC gene transcription. *Nature* 1988; 334:539-542
- Jackson IMD, Lechan RM.** Thyrotropin-releasing hormone. In: *Brain Peptides*, D. T. Krieger, M. J. Brownstein and J. B. Martins, eds., New York. Wiley and Sons, 1983, 661-686
- Jackson IMD, Wu P, Lechan RM.** Immunohistochemical localization in the rat brain of the precursor for thyrotropin releasing hormone. *Science* 1985; 229:1097-1099
- Kambe F, Tsukahara S, Kato T, Seo H.** The Pou-domain protein Oct-1 is widely expressed in adult rat organs. *Biochim Biophys Acta* 1993; 1171:307-310
- Kavlock RJ, Daston GP, DeRosa C, Fenner-Crisp P, Gray LE, Kaattari S, Lucier G, Luster M, Mac MJ, Maczka C, Miller R, Moore J, Rolland R, Scott G, Sheehan DM, Sinks T, Tilson HA.** Research needs for the risk assessment of health and environmental effect of endocrine disruptors: A report of the USEPA-sponsored workshop. *Env Health Perspectives* 1996; 104 (suppl 4):715-740
- Klett M.** Epidemiology of congenital hypothyroidism. *Exp Clin Endocrinol Diabetes* 1997; 105 (Suppl 4):19-23
- Koenig RJ.** Thyroid hormone receptor coactivators and corepressors. *Thyroid* 1998; 8:703-713
- Koenig RJ, Warne RL, Brent GA, Harney JW.** Isolation of a cDNA clone encoding a biologically active thyroid hormone receptor. *Proc Natl Acad Sci USA* 1988; 85:5031-5035
- Kolaja KL, Klaassen CD.** Dose-response examination of UDP-Glucuronosyltransferase inducers and their ability to increase both TGF-B expression and thyroid follicular cell apoptosis. *Toxicol Sci* 1998; 46:31-37
- Koller KJ, Wolff RS, Warden MK, Zoeller RT.** Thyroid hormones regulate levels of thyrotropin-releasing hormone mRNA in the paraventricular nucleus. *Proc Natl Acad Sci USA* 1987; 84:7329-7333
- Kragie L.** Membrane iodothyronine transporters part II: review of protein biochemistry. *Endocr Res* 1996a; 22:95-119
- Kragie L.** Membrane Iodothyronine transporters, Part II: Review of protein biochemistry. *Endocr Res* 1996b; 22:95-119
- Ku LMJd, Sharma-Stokkermans M, Meserve LA.** Thyroxine normalizes polychlorinated biphenyl (PCB) dose-related depression of choline acetyltransferase (ChAT) activity in hippocampus and basal forebrain of 15-day-old rats. *Toxicol* 1994; 94:19-30
- Lazar MA.** Thyroid hormone receptors: multiple forms, multiple possibilities. *Endocr Rev* 1993; 14:184-193
- Lazar MA.** Thyroid hormone receptors: Update 1994. *Endocr Rev Monogr* 1994; 3:280-283
- Lechan RM, Wu P, Jackson IMD.** Immunolocalization of the thyrotropin-releasing hormone prohormone in the rat central nervous system. *Endocrinology* 1986; 119:1210-1216
- Leonard JL, Koehrle J.** Intracellular pathways of iodothyronine metabolism. In: *Werner and Ingbar's The Thyroid, Seventh Edition*, L. E. Braverman and R. D. Utiger, eds., Philadelphia. Lippincott-Raven, 1996, 125-161
- Lippman SS, S.Amr, Weintraub BD.** Discordant effects of thyrotropin (TSH)-releasing hormone on pre- and posttranslational regulation of TSH biosynthesis in rat pituitary. *Endocrinology* 1986; 119:343-348
- Magner JA, Kane J, Chou ET.** Intravenous thyrotropin (TSH)-releasing hormone releases human TSH that is structurally different from basal TSH. *J Clin Endocrinol Metab* 1992; 74:1306-1311
- Mangelsdorf DJ, Evans RM.** The RXR heterodimers and orphan receptors. *Cell* 1995; 83:841-850
- Martin JB, Reichlin S:** Clinical Neuroendocrinology. In: *Contemporary Neurology*. F.A. Davis Company, 1987, pp. 759
- McKinney J, Fannin R, Jordan S, Chae K, Rickenbacher U, Pedersen L.** Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts. *J Med Chem* 1987; 30:79-86
- Mercenthaler I, Liposits Z.** Mapping of thyrotropin-releasing hormone (TRH) neuronal systems of rat forebrain projecting to the median eminence and the OVLT. Immunocytochemistry combined with retrograde labeling at the light and electron microscopic levels. *Acta Biol Hung* 1994; 45:361-374
- Miculan J, Turner S, Paes BA.** Congenital hypothyroidism: diagnosis and management. *Neonatal Netw* 1993; 12:25-34
- Moreau X, Lejeune PJ, Jeanningros R.** Kinetics of red blood cell T3 uptake in hypothyroidism with or without hormonal replacement, in the rat. *J Endocrinol Invest* 1999; 22:257-261
- Morley JE.** Neuroendocrine control of thyrotropin secretion. *Endocrine Rev.* 1981; 2:396-436
- Murray MB, Zilz ND, McCreary NL, MacDonald MJ, Towle HC.** Isolation and characterization of rat cDNA clones for two distinct thyroid hormone receptors. *J Biol Chem* 1988; 263:12770-12777
- Myant NB.** The role of thyroid hormone in the fetal and postnatal development of mammals. In: *Hormones in Development*, M. Hamburg and E. J. Barringtons, eds., New York. Appleton-Century-Crofts, 1971
- Nicholson JL, Altman J.** The effects of early hypo- and hyperthyroidism on the development of rat cerebellar

- cortex. I. Cell proliferation and differentiation. *Brain Res* 1972; 44:13-23
- Oppenheimer JH.** The nuclear receptor-triiodothyronine complex: relationship to thyroid hormone distribution, metabolism, and biological action. In: *Molecular Basis of Thyroid Hormone Action*, J. H. Oppenheimer and H. H. Samuelss, eds., New York. Academic Press, 1983, 1-35
- Oppenheimer JH, Schwartz HL.** Molecular basis of thyroid hormone-dependent brain development. *Endocrine Rev* 1997; 18:462-475
- Oppenheimer JH, Schwartz HL, Strait KA.** Thyroid hormone action 1994: the plot thickens. *Eur J Endocrinol* 1994; 130:15-24
- Perez-Castillo A, Bernal J, Ferreiro B, Pans T.** The early ontogenesis of thyroid hormone receptor in the rat fetus. *Endocrinology* 1985; 117:2457-2461
- Pop VJ, Kuijpers JL, Baar ALv, Verkerk G, Son MMv, Vijlder JJD, Vulsma T, Wiersinga WM, Drexhage HA, Vader HL.** Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. *Clin Endocrinol* 1999; 50:149-155
- Porterfield SP.** Vulnerability of the developing brain to thyroid abnormalities: environmental insults to the thyroid system. *Env Hlth Perspectives* 1994; 102 Suppl 2:125-130
- Porterfield SP, Hendrich CE.** The role of thyroid hormones in prenatal neonatal neurological development-current perspectives. *Endocrine Rev* 1993; 14:94-106
- Porterfield SP, Stein SA.** Thyroid hormones and neurological development: update 1994. *Endocrine Rev* 1994; 3:357-363
- Rapoport B, Spaulding SW.** Mechanism of action of thyrotropin and other thyroid growth factors. In: *Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text*, L. E. Braverman and R. D. Utigers, eds., Philadelphia. Lippincott-Raven, 1986, 207-219
- Rondeel JMM, deGreef WJ, Schoot Pvd, Karels B, Klootwijk W, Visser TJ.** Effect of thyroid status and paraventricular area lesions on the release of thyrotropin-releasing hormone and catecholamines into hypophysial portal blood. *Endocrinology* 1988; 123:523-527
- Rondeel JMM, Greef WJD, Vaart PDMvd, Schoot Pvd, Visser TJ.** *In vivo* hypothalamic release of thyrotropin-releasing hormone after electrical stimulation of the paraventricular area: comparison between push-pull perfusion technique and collection of hypophysial portal blood. *Endocrinology* 1989; 125:971-975
- Roti E, Minelli R, Gardini E, Braverman LE.** The use and misuse of thyroid hormone. *Endocrine Rev* 1993; 14:401-423
- Sap J, Munoz A, Damm K, Goldberg Y, Ghysdael J, Lentz A, Beug H, Vennstrom B.** The c-erbA protein is a high affinity receptor for thyroid hormone. *Nature* 1986; 324:635-640
- Scanlon ME, Toft AD.** Regulation of Thyrotropin Secretion. In: *Werner and Ingbar's The Thyroid, Seventh Edition*, L. E. Braverman and R. D. Utigers, eds., Philadelphia. Lippincott-Raven, 1996, 220-240
- Schussler GC.** The thyroxine-binding proteins. *Thyroid* 2000; 10:141-150
- Schwartz HL, Ross ME, Oppenheimer JH.** Lack of effect of thyroid hormone on late fetal rat brain development. *Endocrinology* 1997; 138:3119-3124
- Schwartz HL, Strait KA, Ling NC, Oppenheimer JH.** Quantitation of rat tissue thyroid hormone binding receptor isoforms by immunoprecipitation of nuclear triiodothyronine binding capacity. *J Biol Chem* 1992; 267:11794-11799
- Seegal RF.** Epidemiological and laboratory evidence of PCB-induced neurotoxicity. *Crit Rev Toxicol* 1996; 26:709-737
- Segersen TP, Hoefler H, Childers H, Wolfe HJ, Wu P, Jackson IMD, Lechan RM.** Localization of thyrotropin-releasing hormone prohormone messenger ribonucleic acid in rat brain by *in situ* hybridization. *Endocrinology* 1987a; 121:98-107
- Segersen TP, Kauer J, Wolfe HC, Mobtaker H, Wu P, Jackson IMD, Lechan RM.** Thyroid hormone regulates TRH biosynthesis in the paraventricular nucleus of the rat hypothalamus. *Science* 1987b; 238:78-80
- Senden NH, Timmer ED, Broers JE, Velde HJvd, Roebroek AJ.** Neuroendocrine-specific protein C (NSP-C): subcellular localization and differential expression in relation to NSP-A. *Eur J Cell Biol* 1996; 69:197-213
- Stockigt JR.** Serum Thyrotropin and thyroid hormone measurements and assessment of thyroid hormone transport. In: *Werner and Ingbar's The Thyroid, Seventh Edition*, L. E. Braverman and R. D. Utigers, eds., Philadelphia. Lippincott-Raven, 1996, 377-396
- Strait KA, Schwartz HL, Perez-Castillo A, Oppenheimer JH.** Relationship of c-erbA content to tissue triiodothyronine nuclear binding capacity and function in developing and adult rats. *J Biol Chem* 1990; 265:10514-10521
- Suresh PA, Sebastian S, George A, Radhakrishnan K.** Subclinical hyperthyroidism and hyperkinetic behavior in children. *Pediatric Neurology* 1999; 20:192-194
- Suzuki N, Peter W, Ciesiolka T, Gruss P, Scholer HR.** Mouse Oct-1 contains a composite homeodomain of human Oct-1 and Oct-2. *Nucl Acids Res* 1993; 21:245-252
- Taurog A.** Hormone Synthesis: Thyroid Iodine Metabolism. In: *Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text*, L. E. Braverman and R. D. Utigers, eds., Philadelphia. Lippincott-Raven, 1996, 47-81
- Taylor T, Gesundheit N, Weintraub BD.** Effects of *in vivo* bolus versus continuous TRH administration on TSH

- secretion, biosynthesis, and glycosylation in normal and hypothyroid rats. *Mol Cell Endocrinol* 1986; 46:253-261
- Taylor T, Weintraub BD.** Thyrotropin (TSH)-releasing hormone regulation of TSH subunit biosynthesis and glycosylation in normal and hypothyroid rat pituitaries. *Endocrinology* 1985; 116:1968-1976
- Taylor T, Wondisford FE, Blaine T, Weintraub BD.** The paraventricular nucleus of the hypothalamus has a major role in thyroid hormone feedback regulation of thyrotropin synthesis and secretion. *Endocrinology* 1990; 126:317-324
- Thompson CC, Weinberger C, Lebo R, Evans RM.** Identification of a novel thyroid hormone receptor expressed in the mammalian central nervous system. *Science* 1987; 237:1610-1614
- Tilson HA, Kodavanti PR, Mundy WR, Bushnell PJ.** Neurotoxicity of environmental chemicals and their mechanism of action. *Toxicol Lett* 1998; 28:631-635
- Tilson HA, Kodavanti PRS.** Neurochemical effects of polychlorinated biphenyls: an overview and identification of research needs. *Neurotoxicology* 1997; 13:727-744
- Timiras PS, Nzekwe EU.** Thyroid hormones and nervous system development. *Biol Neonate* 1989; 55:376-385
- Vanderschueren-Lodeweyckx M, Debruyne F, Dooms L, Eggermont E, Eeckels R.** Sensorineural hearing loss in sporadic congenital hypothyroidism. *Arch Dis Child* 1983; 58:419-422
- Velde HJKvd, Roebroek AJM, Leeuwen FWv, Ven WJMvd.** Molecular analysis of expression in rat brain of NSP-A, a novel neuroendocrine-specific protein of the endoplasmic reticulum. *Mol Brain Res* 1994a; 23:81-92
- Velde HJKvd, Roebroek AJM, Senden NHM, Ramaekers FCS, Ven WJMvd.** NSP-encoded reticulons, neuroendocrine proteins of a novel gene family associated with membranes of the endoplasmic reticulum. *J Cell Sci* 1994b; 107:2403-2416
- Vliet GV.** Neonatal hypothyroidism: Treatment and Outcome. *Thyroid* 1999; 9:79-84
- Vulsma T, Gons MH, deVijlder J.** Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect of thyroid agenesis. *N Engl J Med* 1989; 321:13-16
- Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ, Evans RM.** The c-erbA gene encodes a thyroid hormone receptor. *Nature* 1986; 324:641-646
- Weintraub BD, Gesundheit N, Taylor T, Gyves PW.** Effect of TRH on TSH glycosylation and biological action. *Ann NY Acad Sci* 1989; 553:205-213
- Wondisford FE, Magner JA, Weintraub BD.** Chemistry and Biosynthesis of Thyrotropin. In: *Werner and Ingbar's The Thyroid, Seventh Edition*, L. E. Braverman and R. D. Utiger, eds., Philadelphia. Lippincott and Raven, 1996a, 190-206
- Wondisford FE, Magner JA, Weintraub BD.** Thyrotropin. In: *Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text*, L. E. Braverman and R. D. Utiger, eds., Philadelphia. Lippincott-Raven, 1996b, 190-206
- Zoeller RT, Dowling ALS, Vas A.** Developmental exposure to polychlorinated biphenyls exerts thyroid hormone-like effects on the expression of RC3/Neurogranin and myelin basic protein messenger ribonucleic acids in the developing rat brain. *Endocrinology* 2000; 141:181-189
- Zoeller RT, Kabear N, Albers HE.** Molecular mechanisms of signal integration in hypothalamic neurons. *Amer Zool* 1993; 33:244-254